Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Context Therapeutics (Nasdaq: CNTX), a clinical-stage biopharmaceutical company focused on T cell engaging bispecific antibodies for solid tumors, has granted inducement stock options to two new employees. The grants total 160,000 shares of common stock, awarded outside the company's 2021 Long-Term Performance Incentive Plan. The options were granted on May 5 and May 12, 2025, with exercise prices of $0.839 and $0.78 per share respectively. These 10-year options vest over four years, with 25% vesting after the first year and the remainder vesting monthly over the following three years, contingent on continued employment.
Context Therapeutics (Nasdaq: CNTX), una società biofarmaceutica in fase clinica specializzata in anticorpi bispecifici che coinvolgono le cellule T per tumori solidi, ha concesso opzioni azionarie di incentivo a due nuovi dipendenti. Le opzioni assegnate ammontano a 160.000 azioni ordinarie, concesse al di fuori del Piano di Incentivi a Lungo Termine 2021 dell'azienda. Le opzioni sono state concesse il 5 e il 12 maggio 2025, con prezzi di esercizio rispettivamente di 0,839 $ e 0,78 $ per azione. Queste opzioni con durata decennale maturano in quattro anni, con il 25% che matura dopo il primo anno e il restante che matura mensilmente nei successivi tre anni, a condizione che l'impiego continui.
Context Therapeutics (Nasdaq: CNTX), una compañía biofarmacéutica en etapa clínica enfocada en anticuerpos bispecíficos que involucran células T para tumores sólidos, ha otorgado opciones sobre acciones como incentivo a dos nuevos empleados. Las concesiones totalizan 160,000 acciones ordinarias, otorgadas fuera del Plan de Incentivos de Rendimiento a Largo Plazo 2021 de la empresa. Las opciones se otorgaron el 5 y 12 de mayo de 2025, con precios de ejercicio de $0.839 y $0.78 por acción, respectivamente. Estas opciones con un plazo de 10 años se consolidan durante cuatro años, con un 25% consolidado después del primer año y el resto consolidándose mensualmente durante los siguientes tres años, condicionado a la continuidad del empleo.
Context Therapeutics (나스닥: CNTX)는 고형암을 대상으로 하는 T 세포 결합 이중특이성 항체에 집중하는 임상 단계의 바이오제약 회사로, 두 명의 신입 직원에게 유인 주식 옵션을 부여했습니다. 총 160,000주의 보통주가 회사의 2021년 장기 성과 인센티브 계획 외부에서 부여되었습니다. 옵션은 2025년 5월 5일과 12일에 각각 주당 $0.839와 $0.78의 행사가격으로 부여되었습니다. 이 10년 만기 옵션은 4년에 걸쳐 베스팅되며, 첫 해 후 25%가 베스팅되고 나머지는 이후 3년 동안 매월 베스팅되며, 계속 고용 조건이 충족되어야 합니다.
Context Therapeutics (Nasdaq : CNTX), une société biopharmaceutique en phase clinique spécialisée dans les anticorps bispécifiques engageant les cellules T pour les tumeurs solides, a accordé des options d'achat d'actions à titre d'incitation à deux nouveaux employés. Les attributions totalisent 160 000 actions ordinaires, attribuées en dehors du Plan d'Incitation à la Performance à Long Terme 2021 de la société. Les options ont été accordées les 5 et 12 mai 2025, avec des prix d'exercice respectifs de 0,839 $ et 0,78 $ par action. Ces options d'une durée de 10 ans sont acquises sur une période de quatre ans, avec 25 % acquis après la première année et le reste acquis mensuellement sur les trois années suivantes, sous réserve de la poursuite de l'emploi.
Context Therapeutics (Nasdaq: CNTX), ein biopharmazeutisches Unternehmen in der klinischen Entwicklungsphase, das sich auf T-Zell-aktivierende bispezifische Antikörper für solide Tumoren spezialisiert hat, hat Anreiz-Aktienoptionen an zwei neue Mitarbeiter gewährt. Die Zuteilungen umfassen insgesamt 160.000 Stammaktien, die außerhalb des Long-Term Performance Incentive Plans 2021 des Unternehmens vergeben wurden. Die Optionen wurden am 5. und 12. Mai 2025 mit Ausübungspreisen von 0,839 $ bzw. 0,78 $ pro Aktie gewährt. Diese 10-jährigen Optionen werden über vier Jahre vestet, wobei 25 % nach dem ersten Jahr und der Rest monatlich über die folgenden drei Jahre vestet, vorausgesetzt, die Beschäftigung wird fortgesetzt.
- None.
- None.
PHILADELPHIA, May 12, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors, today announced that Context has granted non-qualified stock option awards to purchase an aggregate of 160,000 shares of its common stock to two new employees as an inducement material for accepting employment with Context.
The stock option awards were granted outside of the Context Therapeutics Inc. 2021 Long-Term Performance Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
The stock options were granted to the new employees on their respective hire dates (May 5, 2025 and May 12, 2025) with an exercise price equal to the closing price of Context’s common stock as reported by Nasdaq on the grant date (
The stock options have a 10-year term and vest over four years, with one-fourth of the shares underlying the stock option vesting on the first anniversary of the grant date and the remainder vesting in thirty-six equal monthly installments thereafter. Vesting of the stock options is subject to continued service with Context through the applicable vesting date.
About Context Therapeutics®
Context Therapeutics Inc. (Nasdaq: CNTX) is a biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies for solid tumors. Context is building an innovative portfolio of TCE bispecific therapeutics, including CTIM-76, a Claudin 6 x CD3 bispecific antibody, CT-95, a Mesothelin x CD3 bispecific antibody, and CT-202, a Nectin-4 x CD3 bispecific antibody. Context is headquartered in Philadelphia. For more information, please visit www.contexttherapeutics.com or follow the Company on X (formerly Twitter) and LinkedIn.
Forward-looking Statements
This press release contains “forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact, included in this press release regarding strategy, future operations, prospects, plans and objectives of management, including words such as “may,” “will,” “expect,” “anticipate,” “look forward,” “plan,” “intend,” and similar expressions (as well as other words or expressions referencing future events, conditions, or circumstances) are forward-looking statements. These include, without limitation, statements regarding (i) the potential benefits, characteristics, safety and side effect profile of our product candidates, (ii) the likelihood data will support future development of our product candidates, and (iii) the likelihood of obtaining regulatory approval for our product candidates. Forward-looking statements in this release involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by the forward-looking statements, and we therefore cannot assure you that our plans, intentions, expectations, or strategies will be attained or achieved. Other factors that may cause actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in our filings with the U.S. Securities and Exchange Commission, including the section titled “Risk Factors” contained therein. Except as otherwise required by law, we disclaim any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events, or circumstances or otherwise.
Investor Relations Contact:
Jennifer Minai-Azary
Context Therapeutics
IR@contexttherapeutics.com
FAQ
What stock options did Context Therapeutics (CNTX) grant to new employees in May 2025?
What is the vesting schedule for Context Therapeutics' (CNTX) May 2025 inducement grants?
How long is the term of Context Therapeutics' (CNTX) May 2025 inducement stock options?
Were Context Therapeutics' (CNTX) May 2025 stock options granted under their 2021 Long-Term Performance Incentive Plan?
